Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)

Background: Systematic data are lacking on the immune response toward SARS-CoV-2 mRNA vaccination in SPMS patients on disease-modifying therapies (DMTs). Objective: The AMA-VACC clinical trial was designed to characterize immune responses to SARS-CoV-2 mRNA vaccines in siponimod-treated SPMS patient...

Full description

Bibliographic Details
Main Authors:	Tjalf Ziemssen, Marie Groth, Benedict Rauser, Tobias Bopp
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-11-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/17562864221135305

Similar Items

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)
by: Tjalf Ziemssen, et al.
Published: (2023-08-01)

Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). <i>Vaccines</i> 2023, <i>11</i>, 1374
by: Tjalf Ziemssen, et al.
Published: (2024-08-01)

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
by: Tjalf Ziemssen, et al.
Published: (2022-12-01)

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
by: Tjalf Ziemssen, et al.
Published: (2024-12-01)

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
by: Tjalf Ziemssen, et al.
Published: (2023-05-01)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
by: Ziemssen, Tjalf, et al.
Published: (2020-07-01)

Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis
by: Victor Constantinescu, et al.
Published: (2024-09-01)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
by: Liesa Regner-Nelke, et al.
Published: (2022-11-01)

SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
by: Georges Katoul Al Rahbani, et al.
Published: (2024-06-01)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
by: Magdalena Mueller-Enz, et al.
Published: (2023-07-01)

Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study
by: Julian Stumpf, et al.
Published: (2022-06-01)

Siponimod in secondary progressive multiple sclerosis
by: Jamir Pitton Rissardo, et al.
Published: (2020-01-01)

Siponimod ameliorates experimental autoimmune neuritis
by: Takafumi Uchi, et al.
Published: (2023-02-01)

Siponimod supports remyelination in the non-supportive environment
by: Johann Krüger, et al.
Published: (2025-02-01)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
by: Newshan Behrangi, et al.
Published: (2019-01-01)

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
by: Christina Woopen, et al.
Published: (2022-07-01)

Does Siponimod Exert Direct Effects in the Central Nervous System?
by: Markus Kipp
Published: (2020-07-01)

Migraine, interferon β1a and siponimod immunomodulator therapies
by: Ashraf A. Dahaba, et al.
Published: (2022-04-01)

THE EFFECT OF Theileria INFECTION ON THE IMMUNE RESPONSES OF CATTLE TO RINDERPEST VACC
by: M.G. Al-Gabban, et al.
Published: (1996-06-01)

Hybrid Immunity Protects against Antibody Fading after SARS-CoV-2mRNA Vaccination in Kidney Transplant Recipients, Dialysis Patients, and Medical Personnel: 9 Months Data from the Prospective, Observational Dia-Vacc Study
by: Julian Stumpf, et al.
Published: (2024-07-01)

Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking
by: Chao Li, et al.
Published: (2024-09-01)

Siponimod-associated cystoid macular edema without known risk factors
by: Min Young Kim, et al.
Published: (2024-12-01)

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01)

Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
by: Johannes B. Goll, et al.
Published: (2023-02-01)

Fostering e-learning in medical education: the EuroVacc team experience
by: Guilherme Andrade Marson, et al.
Published: (2007-01-01)

Fostering e-learning in medical education: the EuroVacc team experience
by: Guilherme Andrade Marson, et al.
Published: (2007-01-01)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
by: Kyra Hamilton, et al.
Published: (2022-01-01)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation.
by: Kyra Hamilton, et al.
Published: (2022-01-01)

Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models
by: Hasan Hüseyin Hendek, et al.
Published: (2024-08-01)

Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer.
by: Waterston, A, et al.
Published: (2005)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
by: Mirjana Radonjic-Simic, et al.
Published: (2021-09-01)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
by: Mirjana Radonjic-Simic, et al.
Published: (2021-08-01)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017-11-01)

Development of immune-specific interaction potentials and their application in the multi-agent-system VaccImm.
by: Anna Lena Woelke, et al.
Published: (2011-01-01)

Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy
by: Lydia Marahrens, et al.
Published: (2017-08-01)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
by: Marc Bigaud, et al.
Published: (2023-05-01)

Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review
by: Qingsheng Li, et al.
Published: (2023-07-01)

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.
by: Paolo Angelo Cortesi, et al.
Published: (2022-01-01)

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
by: Chen Chaoyang, et al.
Published: (2022-05-01)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
by: Apfel Rainer, et al.
Published: (2008-09-01)